MetaVia Inc (Nasdaq:MTVA), a US-based clinical-stage biotechnology company focused on cardiometabolic diseases, announced on Wednesday that the first patient has been dosed in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.

Top-line data is expected in the fourth quarter of 2025.

The randomised, double-blind, placebo-controlled study aims to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. It has enrolled healthy adults with a minimum body mass index (BMI) of 30-45 kg/m2. Nine subjects in each cohort are being randomised in a 6:3 ratio, with each subject receiving either 4 weekly administrations of DA-1726 or placebo. The primary endpoint of the Phase 1 trial is to assess the safety and tolerability of DA-1726 by monitoring adverse events (AEs), serious adverse events (SAEs), treatment emergent adverse events (TEAEs) and AEs leading to treatment discontinuation.